MP-09.08

    October 2006 in “ Urology ”
    Claus Roehrborn, Jeffrey S. Barkin, D. Quast, A.J. Duggan, Kim Major‐Walker, Betsy Morrill
    TLDR The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
    The document discussed the CombAT study, a 4-year investigation comparing the effects of dutasteride (DUT) and tamsulosin (TAM), both individually and combined, on benign prostatic hyperplasia (BPH) symptoms and progression. It aimed to evaluate whether differences in inclusion criteria between CombAT and the previously completed MTOPS study, which examined doxazosin (DOX) and finasteride (FIN), led to a different patient group in CombAT. The analysis focused on comparing the inclusion criteria and baseline parameters of the two studies.
    Discuss this study in the Community →